Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 5/20 | 0.39 |
| ▸ | SLC6A3 | Q01959 | 7/20 | 0.33 |
| ▸ | SLC6A4 | P31645 | 5/20 | 0.33 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.33 |
| ▸ | ABCC9 | O60706 | 1/20 | 0.33 |
| ▸ | ABCC8 | Q09428 | 1/20 | 0.33 |
| ▸ | KCNJ11 | Q14654 | 1/20 | 0.33 |
| ▸ | KCNJ8 | Q15842 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.31 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3828431 | 1.00 | HTR6 (0.39) | HTR6SLC6A3SLC6A4SLC6A2ABCC9 | |
| SCHEMBL3833467 | 0.80 | MDM2 (0.39) | SLC6A3SLC6A4SLC6A2ALDH1A1 | |
| SCHEMBL3833471 | 0.80 | MDM2 (0.39) | SLC6A3SLC6A4SLC6A2ALDH1A1 | |
| SCHEMBL3833602 | 0.80 | HTR6 (0.35) | HTR6SLC6A3SLC6A4SLC6A2ABCC9 | |
| SCHEMBL3833604 | 0.80 | HTR6 (0.35) | HTR6SLC6A3SLC6A4SLC6A2ABCC9 | |
| SCHEMBL3828638 | 0.78 | HTR6 (0.40) | HTR6ALDH1A1MAPK1KMT2A | |
| SCHEMBL3828636 | 0.78 | HTR6 (0.40) | HTR6ALDH1A1MAPK1KMT2A | |
| SCHEMBL13567917 | 0.74 | ALDH1A1 (0.34) | HTR6SLC6A3SLC6A4SLC6A2ALDH1A1 | |
| SCHEMBL13567933 | 0.73 | SLC6A3 (0.35) | HTR6SLC6A3SLC6A4SLC6A2ABCC9 | |
| SCHEMBL3827359 | 0.73 | CACNA1H (0.36) | MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090312310-A1 | Imidazothiazole derivatives | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2009-12-17 | — | — | US | disclosed |
| US-20090312310-A1 | Imidazothiazole derivatives | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2009-12-17 | — | — | US | disclosed |
| US-20090312310-A1 | Imidazothiazole derivatives | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2009-12-17 | — | — | US | disclosed |
| EP-2103619-A1 | IMIDAZOTHIAZOLE DERIVATIVES | Daiichi Sankyo Company, Limited (JP) | 2009-09-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090312310-A1 | Imidazothiazole derivatives | TP53, MDM2, TP53BP1 | HTR6 3973/4885SLC6A3 4833/4885SLC6A4 4784/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.